Table 3 The relationship between clinicopathological characteristics, the systemic inflammatory response and cancer-specific survival in patients with synchronous unresectable colorectal liver metastases; univariate analysis
Patients ( n =84) | Hazard ratio (95% CI) | P -value | |
|---|---|---|---|
Age (<65/65–74/⩾75 years) | 34/27/23 | 1.47 (1.08–2.00) | 0.0139 |
Sex (male/female) | 48/36 | 1.13 (0.70–1.82) | 0.6176 |
Deprivation (1–2/3–5/6–7)a | 7/33/44 | 0.98 (0.85–1.12) | 0.7336 |
Tumour site (colon/rectum) | 52/32 | 1.14 (0.70–1.85) | 0.6048 |
Emergency presentation (no/yes) | 75/9 | 1.56 (0.74–3.27) | 0.2423 |
No. of liver metastases (1/>1) | 4/80 | 2.05 (0.64–6.57) | 0.2270 |
Any single liver metastasis (⩽5/>5 cm) | 36/38 | 2.19 (1.30–3.67) | 0.0030 |
Extra-hepatic disease (no/yes) | 64/20 | 2.06 (1.16–3.67) | 0.0140 |
Therapy: chemotherapy+primary resected or stent/chemotherapy alone/primary resected or stent alone/no active treatment | 28/20/23/13 | 2.16 (1.71–2.73) | <0.0001 |
White cell count (<8.5/8.5–11/>11 × 109 l−1) | 30/27/27 | 1.31 (0.99–1.75) | 0.0631 |
Neutrophil count (<7.5/⩾7.5 × 109 l−1) | 49/35 | 1.57 (0.98–2.53) | 0.0627 |
Lymphocyte count (>3.0/1.0–3.0/<1.0 × 109 l−1) | 2/66/16 | 1.65 (0.93–2.93) | 0.0864 |
Monocyte count (⩽0.9/>0.9 × 109 l−1) | 61/23 | 1.32 (0.77–2.25) | 0.3122 |
Platelet count (<400/⩾400 × 103 l−1) | 55/27 | 1.36 (0.82–2.25) | 0.2338 |
Neutrophil/lymphocyte ratio (<5/⩾5) | 48/36 | 1.35 (0.84–2.16) | 0.2200 |
mGPS (0/1/2) | 17/44/23 | 1.46 (1.05–2.03) | 0.0243 |
